OncoMatch/Clinical Trials/NCT06971523
A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
Is NCT06971523 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CTS3497 for solid tumor.
Treatment: CTS3497 — The primary objective of Phase I of this study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of CTS3497 in patients with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deficient solid tumors and lymphomas. The primary objective of Phase II of this study is to evaluate the efficacy of CTS3497 in patients with metastatic or locally advanced MTAP-deficient solid tumors and lymphomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MTAP deficiency
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care
have failed standard of care (SoC)
Cannot have received: methionine adenosyltransferase 2α (MAT2A) inhibitor
Prior treatment with an methionine adenosyltransferase 2α (MAT2A) inhibitor
Cannot have received: protein arginine methyltransferase 5 (PRMT5) inhibitor
Prior treatment with a protein arginine methyltransferase 5 (PRMT5) inhibitor
Cannot have received: anti-tumor therapy
Anti-tumor therapy within 28 days of study day 1
Lab requirements
Blood counts
adequate hematopoietic function per local laboratory
Kidney function
adequate renal function per local laboratory
Liver function
adequate liver function per local laboratory
Cardiac function
adequate cardiac function per local laboratory
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify